In clinical trials for AD, the delivery of the nerve growth factor via AAV2 to the nucleus basalis of Meynert has demonstrated long-term safety, however, challenges include inefficient delivery to target neurons and potential side effects like nociceptive responses.30 The gene discussed is NGF; the disease is Alzheimer disease.